ATGGFActinogen Med Ltd.

About Actinogen Med Ltd. (ATGGF)

Actinogen Med Ltd. (ATGGF) is a Biotechnology company headquartered in Sydney, NSW, Australia whose shares trade over-the-counter on the Pink tier.

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases.

ATGGF key facts

Ticker symbol

ATGGF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Sydney, NSW, Australia

Country of incorporation

AU

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Actinogen Med Ltd. leadership

• Steven Gourlay — CEO, Managing Director
• Will Souter — CFO
• Peter Webse — Secretary

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with A